

Ian J Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6277509/publications.pdf>

Version: 2024-02-01

188
papers

16,769
citations

22548

61
h-index

17891

125
g-index

192
all docs

192
docs citations

192
times ranked

18691
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 110-118. | 1.1 | 2 |
| 2 | Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. <i>Journal of Medical Genetics</i> , 2022, 59, 632-643. | 1.5 | 33 |
| 3 | Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , 2021, 13, 858. | 1.7 | 6 |
| 4 | UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021, 22, 173. | 0.7 | 4 |
| 5 | Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 2182-2193. | 6.3 | 313 |
| 6 | Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials – an ovarian cancer exemplar. <i>Trials</i> , 2021, 22, 88. | 0.7 | 7 |
| 7 | Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 56.e1-56.e17. | 0.7 | 25 |
| 8 | Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020, 12, 1931. | 1.7 | 18 |
| 9 | Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the “no screen” arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2020, 158, 316-322. | 0.6 | 29 |
| 10 | Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. <i>Diagnostics</i> , 2020, 10, 89. | 1.3 | 5 |
| 11 | Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , 2020, 122, 847-856. | 2.9 | 60 |
| 12 | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , 2019, 121, 483-489. | 2.9 | 32 |
| 13 | The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , 2019, 9, 15787. | 1.6 | 7 |
| 14 | Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400. | 0.7 | 17 |
| 15 | Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , 2019, 26, 1100-1009. | 0.8 | 20 |
| 16 | A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2018, 46, 86-93. | 3.5 | 16 |
| 17 | Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. <i>Journal of Medical Genetics</i> , 2018, 55, 546-554. | 1.5 | 38 |
| 18 | Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733. | 3.2 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. <i>BMJ: British Medical Journal</i> , 2018, 362, k2644. | 2.4 | 43 |
| 20 | Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018, 7, 1241. | 0.8 | 2 |
| 21 | Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , 2017, 116, 501-508. | 2.9 | 86 |
| 22 | The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017, 116, 1111-1117. | 2.9 | 8 |
| 23 | Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 169-177. | 3.5 | 13 |
| 24 | Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5912-5922. | 3.2 | 47 |
| 25 | Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2017, 7, e011822. | 0.8 | 8 |
| 26 | Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603. | 1.2 | 11 |
| 27 | A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017, 117, 666-674. | 2.9 | 47 |
| 28 | Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. <i>BMC Public Health</i> , 2017, 17, 882. | 1.2 | 10 |
| 29 | Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1411-1420. | 0.8 | 148 |
| 30 | Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797. | 0.8 | 13 |
| 31 | Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017, 8, 3811-3825. | 0.8 | 45 |
| 32 | Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , 2016, 11, e0165539. | 1.1 | 8 |
| 33 | Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , 2016, 110, 62-69. | 0.8 | 16 |
| 34 | Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992. | 2.3 | 41 |
| 35 | Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 945-956. | 6.3 | 791 |
| 36 | Genetic screening for gynecological cancer: where are we heading?. <i>Future Oncology</i> , 2016, 12, 207-220. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016, 22, 1734-1743. | 3.2 | 69 |
| 38 | Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , 2015, 2015, 1-6. | 0.9 | 22 |
| 39 | Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1519-1525. | 1.2 | 10 |
| 40 | HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015, 7, 108. | 3.6 | 138 |
| 41 | Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. <i>Clinical Cancer Research</i> , 2015, 21, 622-631. | 3.2 | 158 |
| 42 | Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, 379. | 3.0 | 146 |
| 43 | Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History-Based Testing. <i>Journal of the National Cancer Institute</i> , 2015, 107, 380. | 3.0 | 135 |
| 44 | Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2015, 15, 253. | 1.2 | 9 |
| 45 | Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2062-2071. | 0.8 | 166 |
| 46 | Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. <i>Menopause</i> , 2015, 22, 384-390. | 0.8 | 25 |
| 47 | A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. <i>Journal of Medical Genetics</i> , 2015, 52, 465-475. | 1.5 | 52 |
| 48 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015, 33, 2901-2907. | 0.8 | 266 |
| 49 | Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 311 |
| 50 | Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , 2015, 74, 203-222. | 0.9 | 9 |
| 51 | Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. <i>Journal of Medical Genetics</i> , 2014, 51, 108-113. | 1.5 | 58 |
| 52 | Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e004421. | 0.8 | 15 |
| 53 | Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e005400-e005400. | 0.8 | 8 |
| 54 | Cancer-associated autoantibodies to MUC1 and MUC4: A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 2180-2188. | 2.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47. | 3.6 | 53 |
| 56 | Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014, 8, 982-993. | 0.8 | 41 |
| 57 | In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. <i>BMC Cell Biology</i> , 2013, 14, 43. | 3.0 | 40 |
| 58 | Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 1408-1418. | 1.8 | 96 |
| 59 | Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 472-477. | 0.9 | 14 |
| 60 | Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. <i>PLoS Medicine</i> , 2013, 10, e1001551. | 3.9 | 135 |
| 61 | Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. <i>Journal of Clinical Oncology</i> , 2013, 31, 49-57. | 0.8 | 126 |
| 62 | Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS). <i>Journal of Clinical Oncology</i> , 2013, 31, 107-114. | 0.8 | 10 |
| 63 | The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. <i>PLoS Genetics</i> , 2012, 8, e1002517. | 1.5 | 111 |
| 64 | Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. <i>Journal of the National Cancer Institute</i> , 2012, 104, 114-124. | 3.0 | 49 |
| 65 | Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , 2012, 19, 137-147. | 1.6 | 36 |
| 66 | The UKCTOCS Experience—Reasons for Hope?. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S18-S20. | 1.2 | 20 |
| 67 | Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1555-1562. | 0.8 | 38 |
| 68 | Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , 2012, 1, 245-257. | 1.5 | 14 |
| 69 | Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , 2012, 124, 158-163. | 0.6 | 12 |
| 70 | Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , 2012, , 224-233. | 0.4 | 5 |
| 71 | Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011, 12, 61. | 0.7 | 40 |
| 72 | Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 525-530. | 2.4 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology</i> , The, 2011, 12, 38-48. | 5.1 | 176 |
| 74 | Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. <i>Obstetrics and Gynecology</i> , 2011, 118, 1209-1211. | 1.2 | 13 |
| 75 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074. | 2.3 | 54 |
| 76 | The <i>Sine Qua Non</i> of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. <i>Cancer Prevention Research</i> , 2011, 4, 299-302. | 0.7 | 15 |
| 77 | Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. <i>Carcinogenesis</i> , 2011, 32, 1540-1549. | 1.3 | 36 |
| 78 | A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010, 10, 3388-3392. | 1.3 | 32 |
| 79 | Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 600-604. | 1.1 | 23 |
| 80 | Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. <i>Clinical Chemistry</i> , 2010, 56, 262-271. | 1.5 | 31 |
| 81 | Senescent Fibroblasts Promote Neoplastic Transformation of Partially Transformed Ovarian Epithelial Cells in a Three-dimensional Model of Early Stage Ovarian Cancer. <i>Neoplasia</i> , 2010, 12, 317-IN3. | 2.3 | 78 |
| 82 | Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers. <i>Neoplasia</i> , 2010, 12, 579-IN18. | 2.3 | 38 |
| 83 | Development of a Multimarker Assay for Early Detection of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2159-2166. | 0.8 | 246 |
| 84 | Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , 2010, 20, 440-446. | 2.4 | 740 |
| 85 | Clinical Value of Immunohistochemically Detected Lymphatic and Vascular Invasions in Clinically Staged Endometrioid Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1074-1079. | 1.2 | 21 |
| 86 | Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009, 18, 2297-2304. | 1.4 | 42 |
| 87 | Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , 2009, 18, 1869-1878. | 1.4 | 17 |
| 88 | Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 2349-2357. | 0.4 | 63 |
| 89 | Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1037-1044. | 2.3 | 11 |
| 90 | The clonal evolution of metastases from primary serous epithelial ovarian cancers. <i>International Journal of Cancer</i> , 2009, 124, 1579-1586. | 2.3 | 68 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. <i>International Journal of Cancer</i> , 2009, 125, 2214-2218. | 2.3 | 59 |
| 92 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000. | 9.4 | 276 |
| 93 | Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology</i> , The, 2009, 10, 327-340. | 5.1 | 738 |
| 94 | Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 31-38. | 0.9 | 23 |
| 95 | An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. <i>PLoS ONE</i> , 2009, 4, e8274. | 1.1 | 291 |
| 96 | <i>HOXA11</i> DNA methylationâ€™A novel prognostic biomarker in ovarian cancer. <i>International Journal of Cancer</i> , 2008, 123, 725-729. | 2.3 | 97 |
| 97 | Clinical Value of Immunohistochemically Detected Lymphovascular Space Invasion in Early Stage Cervical Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2581-2588. | 0.7 | 30 |
| 98 | Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. <i>Apmis</i> , 2008, 116, 400-409. | 0.9 | 16 |
| 99 | Predicting Clinical Outcome in Patients Diagnosed with Synchronous Ovarian and Endometrial Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5840-5848. | 3.2 | 41 |
| 100 | The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5833-5839. | 3.2 | 32 |
| 101 | <i>BRCA1</i> and <i>BRCA2</i> Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. <i>Clinical Cancer Research</i> , 2008, 14, 3761-3767. | 3.2 | 92 |
| 102 | Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. <i>BMJ: British Medical Journal</i> , 2008, 337, a2079-a2079. | 2.4 | 128 |
| 103 | Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. <i>PLoS ONE</i> , 2008, 3, e2656. | 1.1 | 131 |
| 104 | Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish â€™MALOVAâ€™ ovarian cancer study. <i>Pathology</i> , 2008, 40, 487-492. | 0.3 | 20 |
| 105 | Distribution of Microsatellite Instability in Danish Ovarian Tumor Patients and the Prognostic Value in Ovarian Cancer Patients. <i>Oncology Research</i> , 2008, 17, 43-49. | 0.6 | 4 |
| 106 | Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. <i>Clinical Chemistry</i> , 2007, 53, 645-656. | 1.5 | 131 |
| 107 | Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 3027-3035. | 0.4 | 78 |
| 108 | Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <i>Menopause</i> , 2007, 14, 462-467. | 0.8 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer. <i>PLoS ONE</i> , 2007, 2, e268. | 1.1 | 54 |
| 110 | Contribution of <i>BRCA1</i> and <i>BRCA2</i> mutations to inherited ovarian cancer. <i>Human Mutation</i> , 2007, 28, 1207-1215. | 1.1 | 76 |
| 111 | Screening for the <i>BRCA1</i> -ins6kbEx13 mutation: potential for misdiagnosis. <i>Human Mutation</i> , 2007, 28, 525-526. | 1.1 | 8 |
| 112 | Serum Peptide Profiling using MALDI Mass Spectrometry. <i>Proteomics</i> , 2007, 7, 77-89. | 1.3 | 51 |
| 113 | Epigenetic stem cell signature in cancer. <i>Nature Genetics</i> , 2007, 39, 157-158. | 9.4 | 1,023 |
| 114 | ESGO statement on cervical cancer vaccination: August 2007. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1183-1185. | 1.2 | 7 |
| 115 | CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. <i>Gynecologic Oncology</i> , 2007, 104, 508-515. | 0.6 | 122 |
| 116 | Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer From the Danish "MALOVA" Ovarian Cancer Study. <i>Gynecologic Oncology</i> , 2007, 106, 318-324. | 0.6 | 19 |
| 117 | Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 107, 526-531. | 0.6 | 96 |
| 118 | Ovarian Cancer Screening. , 2006, , 47-68. | | 1 |
| 119 | Screening for Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2006, 49, 433-447. | 0.6 | 69 |
| 120 | Familial ovarian cancer screening. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 321-338. | 1.4 | 16 |
| 121 | Common Variants in <i>RB1</i> Gene and Risk of Invasive Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 10220-10226. | 0.4 | 39 |
| 122 | Low frequency of <i>BRAF</i> and <i>CDKN2A</i> mutations in endometrial cancer. <i>International Journal of Cancer</i> , 2005, 115, 930-934. | 2.3 | 46 |
| 123 | Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2813-2821. | 0.8 | 327 |
| 124 | Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7919-7926. | 0.8 | 218 |
| 125 | Screening for Familial Ovarian Cancer: The Need for Well-Designed Prospective Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 5443-5445. | 0.8 | 28 |
| 126 | Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions. <i>Journal of Clinical Oncology</i> , 2004, 22, 4059-4066. | 0.8 | 156 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. <i>International Journal of Oncology</i> , 2004, 25, 1615. | 1.4 | 25 |
| 128 | Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. <i>Cancer Research</i> , 2004, 64, 5882-5890. | 0.4 | 884 |
| 129 | A Molecular Genetic and Statistical Approach for the Diagnosis of Dual-Site Cancers. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1441-1446. | 3.0 | 44 |
| 130 | A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. <i>Laboratory Investigation</i> , 2004, 84, 923-931. | 1.7 | 30 |
| 131 | Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. <i>Cancer</i> , 2004, 100, 2387-2395. | 2.0 | 11 |
| 132 | Progress and Challenges in Screening for Early Detection of Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 355-366. | 2.5 | 375 |
| 133 | High-Risk Premenopausal Women's Experiences of Undergoing Prophylactic Oophorectomy: A Descriptive Study. <i>Genetic Testing and Molecular Biomarkers</i> , 2004, 8, 148-156. | 1.7 | 28 |
| 134 | Screening and Diagnosis of Ovarian Cancer in the General Population. , 2004, , 355-368. | | 3 |
| 135 | Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. <i>Gynecologic Oncology</i> , 2003, 91, 218-225. | 0.6 | 16 |
| 136 | MSI-low, a real phenomenon which varies in frequency among cancer types. <i>Journal of Pathology</i> , 2003, 201, 389-394. | 2.1 | 47 |
| 137 | Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. <i>Journal of Pathology</i> , 2003, 201, 544-554. | 2.1 | 127 |
| 138 | Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2003, 21, 206s-210. | 0.8 | 219 |
| 139 | Characterization of Adnexal Mass Lesions on MR Imaging. <i>American Journal of Roentgenology</i> , 2003, 180, 1297-1304. | 1.0 | 186 |
| 140 | CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200. | | 2 |
| 141 | MR Imaging of Carcinoma of the Vulva. <i>American Journal of Roentgenology</i> , 2002, 178, 373-377. | 1.0 | 102 |
| 142 | Ovarian cancer screening. <i>British Journal of Hospital Medicine</i> , 2002, 63, 210-213. | 0.3 | 10 |
| 143 | Management of familial ovarian cancer. , 2002, , 275-285. | | 1 |
| 144 | Screening for familial ovarian cancer. , 2002, , 220-234. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Screening for ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 469-482. | 1.4 | 43 |
| 146 | Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. International Journal of Cancer, 2002, 99, 549-554. | 2.3 | 47 |
| 147 | Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research, 2002, 8, 138-43. | 3.2 | 39 |
| 148 | Survival analysis in familial ovarian cancer, a case control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 98, 219-223. | 0.5 | 21 |
| 149 | Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet, The, 2001, 357, 15-20. | 6.3 | 169 |
| 150 | Ovarian cancer screening in the general population. Current Opinion in Obstetrics and Gynecology, 2001, 13, 61-64. | 0.9 | 36 |
| 151 | Ascites and a Raised Serum Ca 125â€“Confusing Combination. Journal of the Royal Society of Medicine, 2001, 94, 581-582. | 1.1 | 20 |
| 152 | PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer, 2001, 91, 22-26. | 2.3 | 270 |
| 153 | High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). International Journal of Cancer, 2001, 94, 896-900. | 2.3 | 22 |
| 154 | Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma. Laboratory Investigation, 2001, 81, 1363-1370. | 1.7 | 25 |
| 155 | Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Change-point and Mixture Models of Longitudinal Markers. Journal of the American Statistical Association, 2001, 96, 429-439. | 1.8 | 125 |
| 156 | Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 39-42. | 0.9 | 95 |
| 157 | Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer, 2000, 89, 519-523. | 2.3 | 22 |
| 158 | Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1069-1074. | 1.1 | 33 |
| 159 | Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1094-1096. | 1.1 | 10 |
| 160 | Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169. | 1.1 | 64 |
| 161 | Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology, 2000, 15, 350-353. | 0.9 | 26 |
| 162 | Molecular Evidence Linking Primary Cancer of the Fallopian Tube to BRCA1 Germline Mutations. Gynecologic Oncology, 2000, 76, 45-50. | 0.6 | 186 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Registration of ovarian cancer in England and Wales. <i>British Journal of Cancer</i> , 2000, 83, 279-279. | 2.9 | 1 |
| 164 | Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. <i>Cancer</i> , 1999, 85, 2068-2072. | 2.0 | 17 |
| 165 | OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. <i>Clinical Chemistry</i> , 1999, 45, 692-694. | 1.5 | 16 |
| 166 | Role of MR Imaging in the Selection of Patients with Early Cervical Carcinoma for Fertility-preserving Surgery: Initial Experience. <i>Radiology</i> , 1999, 212, 395-399. | 3.6 | 121 |
| 167 | Combination of Multiple Serum Markers Using an Artificial Neural Network to Improve Specificity in Discriminating Malignant from Benign Pelvic Masses. <i>Gynecologic Oncology</i> , 1999, 73, 56-61. | 0.6 | 71 |
| 168 | Increased Mortality in Postmenopausal Women with Serum CA125 Elevation. <i>Gynecologic Oncology</i> , 1999, 73, 242-246. | 0.6 | 9 |
| 169 | Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. , 1999, 85, 2068-2072. | | 12 |
| 170 | Screening for ovarian cancer. <i>Lancet, The</i> , 1999, 354, 510. | 6.3 | 4 |
| 171 | Screening for ovarian cancer: a pilot randomised controlled trial. <i>Lancet, The</i> , 1999, 353, 1207-1210. | 6.3 | 545 |
| 172 | No Evidence Exists for Methylation Inactivation of the p16 Tumor Suppressor Gene in Ovarian Carcinogenesis. <i>Gynecologic Oncology</i> , 1998, 68, 14-17. | 0.6 | 19 |
| 173 | p53 codon 72 polymorphism and risk of cervical cancer in UK. <i>Lancet, The</i> , 1998, 352, 871-872. | 6.3 | 187 |
| 174 | Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. <i>BMJ: British Medical Journal</i> , 1996, 313, 1355-1358. | 2.4 | 164 |
| 175 | Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. <i>Cancer</i> , 1995, 76, 1615-1620. | 2.0 | 18 |
| 176 | Molecular approaches to prevention and detection of epithelial ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 1995, 59, 219-222. | 1.2 | 20 |
| 177 | Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses. <i>Gynecologic Oncology</i> , 1995, 59, 111-116. | 0.6 | 96 |
| 178 | Non-surgical aspects of ovarian cancer. <i>Lancet, The</i> , 1994, 343, 335-340. | 6.3 | 17 |
| 179 | Cell growth regulation in epithelial ovarian cancer. <i>Cancer</i> , 1993, 71, 1597-1601. | 2.0 | 72 |
| 180 | The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1993, 100, 927-931. | 1.1 | 127 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 1120-1124. | 1.1 | 38 |
| 182 | Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 510-515. | 1.1 | 58 |
| 183 | The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction, 1989, 4, 1-12. | 0.4 | 675 |
| 184 | SCREENING FOR EARLY OVARIAN CANCER. Lancet, The, 1988, 332, 171-172. | 6.3 | 4 |
| 185 | Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1988, 29, 73-85. | 0.5 | 72 |
| 186 | MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER. Lancet, The, 1988, 331, 268-271. | 6.3 | 213 |
| 187 | The value of CA 125 serum assay in the management of ovarian cancer. Commentary. BJOG: an International Journal of Obstetrics and Gynaecology, 1987, 94, 819-820. | 1.1 | 3 |
| 188 | Screening for Ovarian Cancer. , 0, , 144-150. | | 0 |